UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000008172 |
|---|---|
| Receipt number | R000009585 |
| Scientific Title | Eicosapentaenoic acid (EPA) for colorectal aberrant crypt foci (ACF): A double-blind randomized controlled trial |
| Date of disclosure of the study information | 2012/06/15 |
| Last modified on | 2013/09/30 00:26:06 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Eicosapentaenoic acid (EPA) for colorectal aberrant crypt foci (ACF): A double-blind randomized controlled trial
Acronym
EPA for colorectal ACF
Scientific Title
Eicosapentaenoic acid (EPA) for colorectal aberrant crypt foci (ACF): A double-blind randomized controlled trial
Scientific Title:Acronym
EPA for colorectal ACF
Region
| Japan |
Condition
Condition
Patients with both colorectal ACF and resectable polyps
Classification by specialty
| Gastroenterology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the chemopreventive effect of EPA against the colorectal ACF
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Phase II,III
Assessment
Primary outcomes
Change of the number of colorectal ACF after 1-months's intervention
Key secondary outcomes
1.The drug safety
2.Mucosal fatty acid analysis
3.The cell-proliferative and apoptotic activities in the rectal epithelium and polyps
4.Laboratory data (HDL-cholesterol, LDL-cholesterol, triglycerides, fatty acid fractions, fasting blood glucose, fasting blood insulin, HbA1c, blood urea nitrogen (BUN), creatinine)
5.physical examination findings (body weight, body mass index (BMI))
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
YES
Dynamic allocation
YES
Institution consideration
Institution is considered as a block.
Blocking
YES
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
receive oral EPA capsule thrice 900 mg, total 2.7g per day for 1 month
Interventions/Control_2
receive oral placebo capsule thrice per day for 1 month
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 40 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1.Patients with both colorectal ACF and resectable polyps.
2.Willingness to provide written informed consent
Key exclusion criteria
1.History of regular use of omega-3 PUFA supplements.
2.History of regular use (defined as at least once per week) of NSAIDs and/or aspirin.
3.History of heart failure, renal failure, liver cirrhosis or chronic hepatic failure
4.History of familial adenomatous polyposis
5.History of hereditary non-polyposis colorectal cancer
6.History of inflammatory bowel disease
7.Pregnancy or possibility of pregnancy
8.Patients judged as inappropriate candidates for the trial by the investigators
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Takuma Higurashi |
Organization
Yokohama City Univesity
Division name
Division of Gastroenterolgy
Zip code
Address
3-9 Fukuura Kanazawa-ku Yokohama City
TEL
045-787-2640
takuma_h@yokohama-cu.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Takuma Higurashi |
Organization
Yokohama City Univesity
Division name
Division of Gastroenterolgy
Zip code
Address
3-9 Fukuura Kanazawa-ku Yokohama City
TEL
045-787-2640
Homepage URL
takuma_h@yokohama-cu.ac.jp
Sponsor or person
Institute
Yokohama City Univesity
Institute
Department
Personal name
Funding Source
Organization
A Grant-in-Aid for research on the Third-Term Comprehensive Control Research for Cancer and (WAKATE-B) from the Ministry of Health, Labour and Welfare, Japan
Organization
Division
Category of Funding Organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
横浜市立大学附属病院
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 06 | Month | 15 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 05 | Month | 31 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 06 | Month | 01 | Day |
Last follow-up date
| 2013 | Year | 08 | Month | 01 | Day |
Date of closure to data entry
| 2013 | Year | 09 | Month | 01 | Day |
Date trial data considered complete
| 2013 | Year | 10 | Month | 01 | Day |
Date analysis concluded
| 2013 | Year | 11 | Month | 01 | Day |
Other
Other related information
Management information
Registered date
| 2012 | Year | 06 | Month | 14 | Day |
Last modified on
| 2013 | Year | 09 | Month | 30 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009585
| Research Plan | |
|---|---|
| Registered date | File name |
| Research case data specifications | |
|---|---|
| Registered date | File name |
| Research case data | |
|---|---|
| Registered date | File name |
